Insight, China's Pharmaceutical Industry

Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA)...

Company Drug

Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer

Fineline Cube Jun 5, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in...

Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026

Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple...

Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026

Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of...

Company Drug

Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments

Fineline Cube Jun 5, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...

Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026

Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...

Company Drug

Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure

Fineline Cube Jun 5, 2026

Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Drug

Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA

Fineline Cube Jun 5, 2026

Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase...

Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026

Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...

Company Drug

Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure

Fineline Cube Jun 5, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Medical Device

GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan

Fineline Cube Jun 5, 2026

GE HealthCare (NASDAQ: GEHC) announced it has received 510(k) clearance from the United States Food...

Company Drug

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Fineline Cube Jun 4, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Fineline Cube Jun 4, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...

Company Deals

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Fineline Cube Jun 4, 2026

H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...

Company Drug

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy

Fineline Cube Jun 4, 2026

Novo Nordisk A/S (NYSE: NVO) announced the market launch of Wegovy (semaglutide) oral tablets in...

Company Deals Medical Device

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...

Company Deals

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Fineline Cube Jun 4, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...

Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Fineline Cube Jun 4, 2026

Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...

Company Medical Device

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, the submission of 510(k) premarket notifications...

Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Fineline Cube Jun 4, 2026

Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...

Insight, China's Pharmaceutical Industry

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients

Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure

Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure

GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

You Missed

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance